Media Coverage

In a move to advance the ground-breaking work to identify coronary heart disease at the earliest transition from wellness to disease, Quest Diagnostics will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative co-founded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca.

Quest Diagnostics has completed its previously announced acquisition of the U.S. laboratory services business of England-based Oxford Immunotec Global PLC, the two companies announced Tuesday. Under terms of the deal, Secaucus-based Quest has purchased the business from Oxford, including the T-SPOT TB tuberculosis and Accutix tick disease testing services provided at labs in Tennessee and Massachusetts.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced that MyQuest, used by more than six million people to see, store and share their results and health information using a smartphone, tablet or desktop computer, now supports Health Records on iPhone. In addition, Quest recently launched a MyQuest update that provides new features such as direct access testing, the ability to add dependents or other approved users, real-time scheduling and more for patients as they become more engaged in managing their healthcare decisions.

Horizon Blue Cross Blue Shield of New Jersey today announced it has renewed its laboratory services relationship with Laboratory Corporation of America and added Quest Diagnostics as an in-network provider of such services.

Horizon Blue Cross Blue Shield of New Jersey will add Quest Diagnostics as an in-network provider of diagnostic information services for its 2.8 million members effective Jan. 1. Quest has more than 300 patient access points in New Jersey and will serve all Horizon members with the exception of managed Medicaid and Dual Eligible Special Needs plan beneficiaries.